JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

Search

Odonate Therapeutics Inc

Fermé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Odonate Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 févr. 2026, 23:52 UTC

Acquisitions, Fusions, Rachats

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 févr. 2026, 23:52 UTC

Acquisitions, Fusions, Rachats

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 févr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 févr. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 févr. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 févr. 2026, 23:23 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 févr. 2026, 22:57 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 févr. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 févr. 2026, 21:51 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 févr. 2026, 21:49 UTC

Résultats

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 févr. 2026, 21:39 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:36 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 févr. 2026, 21:34 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:28 UTC

Acquisitions, Fusions, Rachats

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 févr. 2026, 21:23 UTC

Résultats

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 févr. 2026, 21:19 UTC

Résultats

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 févr. 2026, 21:17 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 févr. 2026, 21:17 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:10 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:08 UTC

Résultats

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 févr. 2026, 21:07 UTC

Résultats

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Net $608.7M >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Rev $1.41B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q EPS 24c >PLTR

2 févr. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparaison

Variation de prix

Odonate Therapeutics Inc prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat